(181 days)
Not Found
No
The summary describes a device that automatically records and classifies arrhythmias based on predefined criteria, but there is no mention of AI or ML algorithms being used for this classification or any other function.
No
The device is described as a monitor that records cardiac arrhythmias, not as a device that treats or provides therapy for them.
Yes
The device is indicated to detect specific cardiac arrhythmias, and it is designed to monitor and record these occurrences to aid in diagnosis.
No
The device description explicitly states it is a "small, leadless, implantable device" that uses "two electrodes on the body of the device" to monitor ECG, indicating it is a hardware device with embedded software, not a software-only medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The BioMonitor 2 is an implantable device that continuously monitors the patient's subcutaneous ECG within the body. It records and classifies cardiac arrhythmias based on electrical signals detected directly from the patient.
- Lack of Sample Analysis: The device does not analyze samples taken from the body. It directly measures physiological signals within the body.
Therefore, the BioMonitor 2 falls under the category of an implantable medical device for physiological monitoring, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The BioMonitor 2 indicated to detect the following cardiac arrhythmias:
- atrial fibrillation
- bradycardia
- sudden rate drop
- high ventricular rate (HVR)
- asystole
The BioMonitor 2 is indicated for use in:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms that may suggest a cardiac arrhythmia
- The device has not been tested for and is not intended for pediatric use
Product codes
MXD
Device Description
The BioMonitor 2 is a small, leadless, implantable device that uses two electrodes on the body of the device to monitor continuously the patient's subcutaneous ECG. The BioMonitor 2 is designed to record automatically the occurrence of arrhythmias in a patient. Recordings can also be triggered by use of the associated Remote Assistant. Arrhythmia may be classified as atrial fibrillation, bradycardia, asystole, or high ventricular rate. The device memory can automatically store a maximum of 55 separately recorded SECG-episodes of 40 seconds each, and 4 patient triggered SECG-episodes of 7.5 minutes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
subcutaneous
Indicated Patient Age Range
The device has not been tested for and is not intended for pediatric use
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Software Verification and Validation Testing
Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" in a separate submission. The software for this device was considered as a "major" level of concern, since a failure or latent flaw in the software could directly result in serious injury or death to the patient or operator.
3.0T MRI Scan Testing
BIOTRONIK conducted validation testing according to the Joint Working Group's International Technical Specification for ISO/TS 10974: 2012 (E). The following tests were performed:
- Gradient Induced Heating
- Vibration
- Static Malfunction
- Gradient Radiated Malfunction
- Vibration Malfunction
Clinical Study
The objective of this study was to provide clinical data of the implantation procedure and the sensing quality of BIOTRONIK's second generation of Implantable Cardiac Monitor (ICM) BioMonitor 2. Data from 30 patients at 5 Australian clinical sites from December 18, 2014 through July 06, 2015 is included to support the substantial equivalence of BioMonitor 2 when compared to the predicate device. Additional implantations have commenced recently in Europe as part of a controlled Post Market Observation (PMO), as of October 9, 2015 there have been 15 implantations.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is often associated with healthcare. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol. The logo is presented in black and white.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 11, 2016
Biotronik, Inc. Jon Brumbaugh Vice President, Regulatory Affairs and Compliance 6024 Jean Road Lake Oswego, Oregon 97035
Re: K152995
Trade/Device Name: BioMonitor 2 Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm) Regulatory Class: Class II Product Code: MXD Dated: March 10. 2016 Received: March 11, 2016
Dear Jon Brumbaugh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mitchell Stein
forBram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K152995 - Page 1 of 1
Device Name BioMonitor 2
Indications for Use (Describe)
The BioMonitor 2 indicated to detect the following cardiac arrhythmias:
-
atrial fibrillation
-
bradycardia
-
sudden rate drop
-
high ventricular rate (HVR)
-
asystole
The BioMonitor 2 is indicated for use in:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms that may suggest a cardiac arrhythmia
- The device has not been tested for and is not intended for pediatric use
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
BioMonitor 2 Implantable Cardiac Monitor
Traditional 510(k) Premarket Notification
1. SUBMISSION INFORMATION
| Date 510(k) Summary Prepared: | October 9, 2015 |
|---|---|
| Name and Address of Sponsor: | BIOTRONIK, Inc. |
| 6024 Jean Road | |
| Lake Oswego, OR 97035 | |
| Establishment Registration Number: | 1028232 |
| Name and Address of Manufacturer: | BIOTRONIK SE & Co. KG (reg. no. 9610139) |
| Woermannkehre 1, | |
| 12359 Berlin, Germany | |
| 011-49-30-689-05-1210 |
Sterigenics Germany GmbH
Kasteler Straße 45
D- 65203 Wiesbaden, Germany |
| Contact Person(s) and Phone Number: | Jon Brumbaugh
VP, Regulatory Affairs and Compliance
Phone (888) 345-0374
Fax (800) 913-6993
jon.brumbaugh@biotronik.com |
| Device Name: | Trade Name: BioMonitor 2
Common Name: Implantable Cardiac Monitor
Classification Name: Arrhythmia detector and alarm (including ST-segment
measurement and alarm).
Classification: Class II (21 CFR 870.1025)
Product Code: MXD |
General Description:
The BioMonitor 2 is a small, leadless, implantable device that uses two electrodes on the body of the device to monitor continuously the patient's subcutaneous ECG. The BioMonitor 2 is designed to record automaticallythe occurrence of arrhythmias in a patient. Recordings can also be triggered by use of the associated Remote Assistant. Arrhythmia may be classified as atrial fibrillation, bradycardia, asystole, or high ventricular rate. The device memory can automatically store a maximum of 55 separately recorded SECG-episodes of 40 seconds each, and 4 patient triggered SECG-episodes of 7.5 minutes.
4
Predicate Devices:
- BIOTRONIK BioMonitor with AF Detection (K143503, cleared March 19, 2015) ●
Indication for Use:
The BioMonitor 2 is indicated to detect the following cardiac arrhythmias:
- atrial fibrillation ●
- bradycardia,
- . sudden rate drop,
- high ventricular rate (HVR), ●
- asystole. ●
The BioMonitor 2 is indicated for use in:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias .
- Patients who experience transient symptoms that may suggest a cardiac arrhythmia ●
- The device has not been tested for and it is not intended for pediatric use ●
Technological Characteristics and Substantial Equivalence:
The substantial equivalence claim between the subject and the predicate device is supported by the information included in this premarket notification. This includes the following information:
- Description of the subject and predicate devices -
- -Intended use of the subject and predicate devices
- -Performance of the subject and predicate devices
- -Technological characteristics of the subject and predicate devices
- -Validation testing
5
Table 1: BioMonitor 2 Compared to Predicate Device (changes are highlighted)
| Technical Data | BioMonitor | BioMonitor 2 |
|---|---|---|
| FDA Clearance | K143503 | Subject |
| Dimensions (mm) | 53.3 x 42.7 x 7.1 | 88.4 x 15.2 x 6.2 |
| Length x Width x Height | Rigid portion 55.5 x 15.2 x 6.2 | |
| Volume | 12.5 cc | 5 cc |
| Weight | 26 g | 10.1 g |
| Longevity | 48 months (+ 12 months pre-implant shelf life + 2 months ERI life) | |
| Subcutaneous ECG Recording | Yes | |
| Pre and Post Event Storage | Yes | |
| sECG Storage | 35.8 min | |
| 22.5 min for patient | ||
| triggered events | ||
| 13.3 min for auto- | ||
| activated events | ||
| Longest/oldest/newest | >66 min | |
| 30 min for patient triggered events | ||
| 36.7 min for auto-activated events | ||
| Longest/oldest/newest | ||
| Patient Activation | 7.5 min per event | |
| 7 min prior to activation | ||
| 0.5 min following activation | ||
| Asystole | ||
| Brady/rate drop | ||
| VT-FVT | 40 s/episode | |
| 30 s prior auto activation | ||
| 10 s post auto activation | ||
| AF | 40 s/episode | |
| 30 s prior auto activation | ||
| 10 s post auto activation | ||
| Vector Mapping Required | No | |
| Sampling Rate | 128 Hz | |
| Auto Activation Triggers | Yes | |
| Manual (Patient) Activation | ||
| Trigger | Yes - via magnet | Yes - via Remote Assistant |
| High Rate Trigger | Yes | |
| Programmable High Rate Count | Yes | |
| Low Rate Trigger | Yes | |
| Asystole Trigger | Yes | |
| Remote Monitoring | Home Monitoring daily | |
| transmissions, up to 1 | ||
| episode per day | Home Monitoring daily transmissions, up | |
| to 6 episodes (at least one per triggered | ||
| event type) per day | ||
| QRS Detection | Combination signal out of | |
| 3 vectors | Single vector | |
| MR Conditional | 1.5T, full body scan | 1.5T and 3.0T, fully body scan |
Performance Data:
The following performance data were provided in support of the substantial equivalence determination.
6
Software Verification and Validation Testing
Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" in a separate submission. The software for this device was considered as a "major" level of concern, since a failure or latent flaw in the software could directly result in serious injury or death to the patient or operator.
3.0T MRI Scan Testing
BIOTRONIK conducted validation testing according to the Joint Working Group's International Technical Specification for ISO/TS 10974: 2012 (E). The following tests were performed:
- ·Gradient Induced Heating
- •Vibration
- ·Static Malfunction
- •Gradient Radiated Malfunction
- •Vibration Malfunction
Clinical Study
The objective of this study was to provide clinical data of the implantation procedure and the sensing quality of BIOTRONIK's second generation of Implantable Cardiac Monitor (ICM) BioMonitor 2. Data from 30 patients at 5 Australian clinical sites from December 18, 2014 through July 06, 2015 is included to support the substantial equivalence of BioMonitor 2 when compared to the predicate device. Additional implantations have commenced recently in Europe as part of a controlled Post Market Observation (PMO), as of October 9, 2015 there have been 15 implantations.
List of Applied Standards
The BioMonitor 2 was tested in accordance with the following standards:
- EN 45502-1 (1997) Section 21
- EN 45502-2-1 (2003) Section 6.1.3 ●
- . ISO 11135-1 (2007)
- ISO 14708-1 (2014) ●
- . ISO/TS 10974 (2012)
Conclusion:
BIOTRONIK considers the BioMonitor 2 implantable cardiac monitor to be substantially equivalent to legally marketed predicate devices through the data and information presented. No safety or effectiveness issues were identified.